Page 6 - ட்யாஂடம் நீரிழிவு நோய் பராமரிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Outlook on the Needle Free Diabetes Management Global Market to 2029 - Development of Next Generation Glucose Sensors Presents Opportunities

Share this article Share this article ResearchAndMarkets.com s offering. This report titled needle free diabetes management market studies various device types such as treatment devices, diagnostic devices and artificial pancreas that respectively sub-segmented. According to the International Diabetes Federation, in 2015 one in 11 adult has diabetes and by 2040 it is expected that one in 10 adults will have diabetes. The data suggests that in 2015 every 6 seconds one person dies from diabetes. Thus, diabetes management is one of the most crucial parts to prevent life threatening effects of this disease. The ongoing research and development activities in field of diagnosis and treatment of diabetes are expected to change the aspect of market in coming years.

United statesSouth koreaAsia pacificLaura woodTechnologies ltdZogenix incFinancial healthCompany snapshot business descriptionInternational diabetes federationBioject medical technologies incTandem diabetes care incOffice hours callMedtronic incDevelopment of next generation glucose sensorsPharmajet incCompany profiles

Analysts Have Conflicting Sentiments on These Healthcare Companies: Atricure (NASDAQ: ATRC), Becton Dickinson (NYSE: BDX) and Illumina (NASDAQ: ILMN)

Atricure (ATRC) In a report issued on April 27, Danielle Antalffy from Leerink Partners maintained a Buy rating on Atricure, with a price target of $78.00. The company’s shares closed last Wednesday at $69.85, close to its 52-week high of $72.07. According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 25.9% and a 70.9% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Tandem Diabetes Care, and Edwards Lifesciences. Atricure has an analyst consensus of Strong Buy, with a price target consensus of $75.57, representing a 15.3% upside. In a report issued on April 27, Oppenheimer also maintained a Buy rating on the stock with a $75.00 price target.

Canaccord genuityRichard newitterBecton dickinsonPuneet soudaCastle biosciencesAbcellera biologicsEdwards lifesciencesDanielle antalffyZimmer biomet holdingsOrganogenesis holdingsResearch reportLeerink partnersAxonics modulation technologiesTandem diabetes careStrong buyInspire medical systems

Digital Diabetes Management Market Research Report by Type, by Product, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19

Digital Diabetes Management Market Research Report by Type, by Product, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomSouth africaUnited arab emiratesSaudi arabiaSouth koreaB braun melsungenGlooko incAscensia diabetes care holdingsCare innovationsDariohealth corpProduct development innovationMarket developmentOrpyx medical technologies incDexcom inc

Tempo lands $200M for digital fitness studio, Benchling scores $200M for pharma research platform and other digital health fundings

Photo by IronHeart/Getty Images At-home digital fitness studio Tempo has raised $220 million in its recently closed Series C funding round. SoftBank Vision Fund 2 led the round with additional participation from new investor Steadfast Capital Ventures and returning investors DCM, General Catalyst, Norwest Venture Partners, and Bling Capital. Tempo plans to use the money to continue enhancing its artificial intelligence and 3D sensor tracking technology. The company’s flagship workout device scans users 30 times per second to guide users through the session while correcting their form when necessary. Coming less than a year after its $60 million raise, Tempo now has nearly $300 million in funding to date.

United statesPalo altoCarine carmyPatrick fuMichelle longmireRoy beveridgeAndreessen horowitzElad gilAnnie lamontSoftbank vision fundSchroder coBlue venture fundYpsomed groupBank vision fundSteadfast capital venturesGeneral catalyst

A String of Developments in the Diabetes Management Space

CeQur, Medtronic, Roche, and Biocorp made moves in the diabetes market. CeQur has raised $115 million in an oversubscribed equity financing. The Lucerne, Switzerland-based company has developed CeQur Simplicity, a wearable insulin delivery system. Credit Suisse Entrepreneur Capital Ltd. and Endeavour Vision led the financing with significant participation from new investors, including Tandem Diabetes Care, Ypsomed Group, Federated Hermes Kaufmann Funds, Kingdon Capital, and GMS Capital, as well as existing investors, Schroder & Co. Bank SA, and VI Partners. Proceeds from the financing will be used to advance commercial plans for CeQur Simplicity, including market development activities, a phased commercial launch strategy that includes a limited market release in 2021, and the scale-up of high-volume manufacturing.

John sheridanEric dessertenneCredit suisse entrepreneur capital ltdSchroder coYpsomed groupCequr simplicitySuisse entrepreneur capitalEndeavour visionTandem diabetes careFederated hermes kaufmann fundsKingdon capitalQur simplicityRoche diabetes care franceRoche diabetes careஜான் ஷெரிடன்கடன் ஸ்யூயி தொழில்முனைவோர் மூலதனம் லிமிடெட்